Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 11:25 p.m.

    📋 Terns Pharmaceuticals, Inc. (TERN) - Financial Results

    Filing Date: 2022-08-08

    Accepted: 2022-08-08 16:19:40

    Event Type: Financial Results

    Event Details:

    Terns Pharmaceuticals Inc (TERN) Reports Q3 2022 Financial Results Terns Pharmaceuticals Inc (TERN) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 139810
      • 701: Oral, allosteric BCR
      • ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia
      • In May 2022, Hansoh Pharmaceutical Group Company Limited (Hansoh) initiated dosing of TERN
        • expected in the second half of 2023
        • expected in 2023
        • expected in second half of 2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 10.82K 27.91K $-17.09K -61.24%
    Operating Expenses Interest Income 55.00 283.00 $-228.00 -80.57%
    Operating Expenses Net Loss 10.74K 27.70K $-16.96K -61.24%
    Cash Equivalents Marketable Securities 139.81K 165.98K $-26.17K -15.77%
    Loss from Operations 14.08K 10.82K $3.27K +30.19%
    Interest Income 214.00 55.00 $159.00 +289.09%
    Net Loss 13.93K 10.74K $3.19K +29.73%
    Cash and Marketable Securities 139.81K 165.98K $-26.17K -15.77%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Terns Pharmaceuticals Inc
    • CIK: 0001831363
    • Ticker Symbol: TERN
    • Period End Date: 2022-08-08
    • Document Type: 8-K

Search

News categories